ImmunityBio, Inc. and NantKwest, Inc. merged on March 9, 2021 to create a leading late-stage, cell therapy and immunotherapy company focused on oncology and infectious diseases. The combined company is called ImmunityBio, Inc. (NASDAQ: IBRX).
Data Provided by Refinitiv. Minimum 15 minutes delayed.
ImmunityBio Investor Relations
Phone: 1-844-696-5235, Option 5
Transfer Agent & Stockholder Services
American Stock Transfer & Trust Company, LLC
AST Shareholder Services Call Center
Toll Free: 800.937.5449
Local & International: 718-921-8124
Hours: 8 a.m. – 8 p.m. ET Monday-Friday